This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
NTT DOCOMO's Race to 5G
Alcacer, Juan; Melcher, Horst; Kanno, AkikoCase HBS-720413-EStrategyWhat new services could they offer? Should they target corporate customers? Can NTT DOCOMO return to a sustainable growth path through 5G? How can they capture a larger share of the value created through 5G enabled internet ecosystems?Starting at €8.20
-
Hitachi Rail Limited (B)
Collis, David J.; Kanno, Akiko; Sato, NobuoCase HBS-721365-EStrategyDescribes the strategy and organisation changes made by British executive, Alistair Domer, after he is made head of Hitachi Rail's global business. The company acquires an Italian company, continues to win contracts in the UK, but struggles to bring its gStarting at €5.74
-
Oriental Land Co., Ltd. -Tokyo Disney Resort
Casadesus-Masanell, Ramon; Kanno, AkikoCase HBS-720460-EStrategyThis case describes the history of Oriental Land Co. Ltd.'s (OLC's) Tokyo Disney Resort (TDR), its operations, the extent of vertical integration, and the challenges it faced in 2018 as OLC's chairman and CEO, Toshio Kagami, contemplated how best to dealStarting at €8.20
-
Takeda Pharmaceutical Company Limited (B)
Collis, David J.; Sato, Nobuo; Kanno, AkikoCase HBS-721374-EStrategyThis case is a follow up to HBS Case No. 721-373, Takeda Pharmaceutical Company Limited (A). Following the events of the previous case, Takeda reached an agreement to acquire Ireland-based Shire Plc. The case follows some of the achievements and challengeStarting at €5.74
-
Hitachi Rail Limited (A)
Collis, David J.; Kanno, Akiko; Sato, NobuoCase HBS-721364-EStrategyHitachi must decide whether to make a British executive, who has successfully built its European rail business from scratch, head of its global rail division even though the bulk of revenues for the unit still come from Japan. The case describes, the histStarting at €8.20
-
Takeda Pharmaceutical Company Limited (A)
Collis, David J.; Sato, Nobuo; Kanno, AkikoCase HBS-721373-EStrategyThis case follows Christophe Weber, President and CEO of Takeda Pharmaceutical Company Limited, a leading pharmaceutical company headquartered in Tokyo, Japan, as Takeda considers acquiring Shire Plc, a biotech company based in Ireland. The acquisition woStarting at €8.20